News of Note—Sanofi's Dengvaxia, flu vaccines and more

Here is some other vaccine news of note for the week.

> An examination of documents filed in Singapore showed that Sanofi Pasteur was aware in October 2016 that Dengvaxia shouldn’t be given to those who haven’t had dengue, according to a Philippine official. A company executive said the document outlined possible or "theoretical" risks. CNN article | Inquirer article 

> The WHO has recommended changing two flu strains currently included in flu vaccines for the next season, and an FDA advisory committee will determine whether to apply them for the U.S. WHO recommendation | FDA statement

> Supported by a £4.7 million government award, the University of Liverpool is leading a collaborative project to develop a Zika vaccine suitable for pregnant women. Release

> Emergent BioSolutions and partner Valneva have advanced their Zika vaccine candidate into human testing. Release

> South Korea’s SK Chemicals, which recently licensed its cell-based flu vaccine technology to Sanofi, plans to spin off its vaccine business into a separate subsidiary. Korea Biomedical Review article

> The Association of the British Pharmaceutical Industry said a U.K. government proposal on the methodology used to assess immunization programs would make it harder for people to access vaccines. ABPI statement